Tag: SARS-CoV-2

1. In Washington State, pregnant patients were found to be at a higher risk of SARS-CoV-2 infection. 2. Results were more pronounced if patients belonged to a non-white racial or ethnic group or received their care in a language other than English. Evidence Level Rating: 2 (Good) As the COVID-19 pandemic continues to...
1. Efficacy of the Gam-COVID-Vac (Sputnik V) vaccine against COVID-19 was 91.6%. 2. In the vaccine group, there were no confirmed cases of moderate or severe COVID-19 21 days after the first dose. Evidence Rating Level: 1 (Excellent) Study Rundown: Global efforts to develop safe and effective vaccines for COVID-19 prevention are...
1. Novel SARS-CoV-2 vaccine SCB-2019 was well-tolerated amongst both younger and older adults. 2. SCB-2019 adjuvanted with AS03 or CpG/Alum elicited strong humoral and cellular responses.  Evidence Rating Level: 1 (Excellent) Study Rundown: As the global pandemic of SARS-CoV-2 (COVID-19) continues to ravage healthcare systems around the world, the effort to produce...
1. Polypharmacy in non-care home residents was strongly associated with higher rates of severe COVID-19. Evidence Rating Level: 3 (Average) Resistant hypertension, which is uncontrolled despite maximal medical therapy, affects up to 10% of patients diagnosed with hypertension. Renal artery denervation has been demonstrated in a number of smaller, nonrandomized and/or...
1. Patients hospitalized with COVID-19 and treated with dexamethasone showed an overall decrease in 28-day mortality compared to those treated with usual care. 2. Dexamethasone treatment had a shorter duration in hospital stay compared to the usual care group. Evidence Rating Level: 1 (Excellent) Study Rundown: Although the majority of coronavirus disease...
1. Majority of the patients that received high-titer convalescent plasma within 72 hours of mild symptom onset were shown to reduce the coronavirus disease 2019 (COVID-19) severe illness progression. 2. The IgG titer distribution between the treatment group and placebo group revealed a significant difference. Evidence Rating Level: 1 (Excellent) Study Rundown: The number...
1. All-cause mortality at 28 days was similar between patients in the azithromycin group and usual care alone group. 2. There was no significant difference in the duration of hospital stay or the proportion of patients discharged alive at 28 days. Evidence Rating Level: 1 (Excellent) Study Rundown: Corticosteroids are often used...
1. Majority of the patients that received high-titer convalescent plasma within 72 hours of mild symptom onset were shown to reduce the coronavirus disease 2019 (COVID-19) severe illness progression. 2. The IgG titer distribution between the treatment group and placebo group revealed a significant difference. Evidence Rating Level: 1 (Excellent) Study Rundown:...
1. Health care workers with anti-spike antibodies revealed no symptomatic infections during the follow-up period for at least six months. 2. Participants with anti-nucleocapsid IgG antibodies also displayed a lower risk of reinfection of COVID-19 disease during the follow-up period. Evidence Rating Level: 2 (Good) Study Rundown: Vaccines have been great with combating the...
1. Black, Hispanic, and Asian patients had significantly higher infection rates for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compared to White patients. 2. Asian and Hispanic patients had greater severity of illness at admission compared to White patients. Evidence Rating Level: 2 (Good) Study Rundown: Coronavirus disease 2019 (COVID-19) has been...